» Articles » PMID: 22346787

Anti-CD137 MAb Deletes Both Donor CD4 and CD8 T Cells in Acute Graft-versus-host Disease

Overview
Journal Immune Netw
Date 2012 Feb 21
PMID 22346787
Authors
Affiliations
Soon will be listed here.
Abstract

We previously demonstrated that in vivo engagement of CD137, a member of TNF receptor superfamily, can delete allorective CD4(+) T cells through the induction of activation-induced cell death (AICD) in chronic graft-versus-host disease (cGVHD) and subsequently reverse established cGVHD. In this study, we further showed that agonistic anti-CD137 mAb was highly effective in triggering AICD of donor CD8(+) T cells as well as donor CD4(+) T cells in the C57BL/6→unirradiated (C57BL/6 × DBA/2)F1 acute GVHD model. Our results suggest that strong allostimulation should facilitate AICD of both alloreactive CD4(+) and CD8(+) T cells induced by CD137 stimulation. Therefore, depletion of pathogenic T cells using agonistic anti-CD137 mAb combined with potent TCR stimulation may be used to block autoimmune or inflammatory diseases mediated by T cells.

References
1.
Zhang B, Maris C, Foell J, Whitmire J, Niu L, Song J . Immune suppression or enhancement by CD137 T cell costimulation during acute viral infection is time dependent. J Clin Invest. 2007; 117(10):3029-41. PMC: 1974869. DOI: 10.1172/JCI32426. View

2.
Kim J, Choi W, La S, Suh J, Kim B, Cho H . Stimulation with 4-1BB (CD137) inhibits chronic graft-versus-host disease by inducing activation-induced cell death of donor CD4+ T cells. Blood. 2004; 105(5):2206-13. DOI: 10.1182/blood-2004-06-2080. View

3.
Kwon B . CD137-CD137 Ligand Interactions in Inflammation. Immune Netw. 2010; 9(3):84-9. PMC: 2803301. DOI: 10.4110/in.2009.9.3.84. View

4.
Kim J, Kim H, Park K, Kim J, Choi H, Yagita H . Costimulatory molecule-targeted immunotherapy of cutaneous graft-versus-host disease. Blood. 2007; 110(2):776-82. DOI: 10.1182/blood-2006-08-043612. View

5.
Melero I, Shuford W, Newby S, Aruffo A, Ledbetter J, Hellstrom K . Monoclonal antibodies against the 4-1BB T-cell activation molecule eradicate established tumors. Nat Med. 1997; 3(6):682-5. DOI: 10.1038/nm0697-682. View